Dahri Monireh, Sarafan Sadeghi Atefeh, Pahlavani Naseh, Nattagh-Eshtivani Elyas, Hashemilar Mazyar, Asghari-Jafarabadi Mohammad, Barghchi Hanieh, Tarighat-Esfanjani Ali
Department of Nutrition Sciences, Varastegan Institute of Medical Sciences, Mashhad 9179667680, Iran.
Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh 9516915169, Iran.
Clin Nutr Res. 2023 Oct 31;12(4):257-268. doi: 10.7762/cnr.2023.12.4.257. eCollection 2023 Oct.
Migraine is a common neurological disease correlated with oxidative stress and lipid profile disorders. The present study was designed to determine the effects of Coenzyme Q10 (Co-Q10) supplementation on oxidative status and lipid profile in migraine individuals. This clinical trial was conducted on 84 females aged 18-50 years, diagnosed for episodic migraine according to the International Headache Society. Subjects were randomized to receive either Co-Q10 supplement (400 mg/day) or placebo for 12 weeks. Lipid profile and oxidative stress indices including malondialdehyde (MDA) and total antioxidant capacity (TAC) were measured before and after intervention in both groups. Also, anthropometric indices, dietary intakes, and clinical features were collected. Data analysis was conducted using SPSS version 16. Seventy-seven of the participants, with mean age of 33.70 ± 7.75 years, completed the study. After 12-week intervention, Co-Q10 led to a significant decrease in MDA levels compared to placebo (p = 0.009), with no effect on TAC levels (p = 0.106). A significant increase in serum Co-Q10 concentration and high-density lipoprotein cholesterol (HDL-C) level in Co-Q10 group was observed, but no significant differences were found in other lipid profile variables (low-density lipoprotein cholesterol, triglycerides and total cholesterol). Among anthropometric variables, Co-Q10 only caused a significant reduction in body fat percentage (BFP), but we did not find any significant changes in others. A 12-week Co-Q10 supplementation led to significant improvement in clinical features, BFP, and HDL-C level among migraine individuals.
Iranian Registry of Clinical Trials Identifier: IRCT201508265670N10.
偏头痛是一种与氧化应激和脂质谱紊乱相关的常见神经系统疾病。本研究旨在确定补充辅酶Q10（Co-Q10）对偏头痛患者氧化状态和脂质谱的影响。本临床试验针对84名年龄在18至50岁之间、根据国际头痛协会诊断为发作性偏头痛的女性进行。受试者被随机分为接受Co-Q10补充剂（400毫克/天）或安慰剂，为期12周。在两组干预前后测量脂质谱和氧化应激指标，包括丙二醛（MDA）和总抗氧化能力（TAC）。此外，还收集了人体测量指标、饮食摄入量和临床特征。使用SPSS 16版进行数据分析。77名参与者完成了研究，平均年龄为33.70±7.75岁。经过12周的干预，与安慰剂相比，Co-Q10导致MDA水平显著降低（p = 0.009），对TAC水平无影响（p = 0.106）。观察到Co-Q10组血清Co-Q10浓度和高密度脂蛋白胆固醇（HDL-C）水平显著升高，但在其他脂质谱变量（低密度脂蛋白胆固醇、甘油三酯和总胆固醇）中未发现显著差异。在人体测量变量中，Co-Q10仅导致体脂百分比（BFP）显著降低，但我们未发现其他变量有任何显著变化。为期12周的Co-Q10补充剂导致偏头痛患者的临床特征、BFP和HDL-C水平显著改善。
伊朗临床试验注册中心标识符：IRCT201508265670N10。
